Long-term survival of patients with HIV-related systemic non-Hodgkin's lymphomas

Hematological Oncology
Umberto TirelliAntonino Carbone

Abstract

the overall outcome of patients with HIV-related non-Hodgkin's lymphomas (HIV-NHL) is poor because of the adverse clinico-pathological features of HIV-NHL and the underlying HIV infection. However, the experience of physicians in the management of HIV-NHL has increased, in particular in the use of intensive chemotherapy regimens, leading to an improvement in the prognosis of some of these neoplasms. Because some patients with AIDS may survive up to 5 years, it is possible to evaluate the long-term efficacy of the treatment of patients with HIV-NHL. In the general population, aggressive NHL, that are those occurring in HIV patients, may be considered cured after 2 years of lasting complete remission (CR) after chemotherapy. we reviewed our monoinstitutional case-series of 73 HIV-infected patients with systemic NHL, observed between April 1985 and February 1993. Two groups of patients were arbitrarily identified, the first one (group A) including patients with a CR lasting for at least 2 years (N = 13) and the other including all remaining patients (group B) (N = 60). the 13 patients of group A differed significantly from the other patients in terms of higher CD4+ cell count and performance status (PS) at the time of diagnosis of...Continue Reading

Citations

Jan 1, 1996·Pathology Oncology Research : POR·Kathryn Fife, Mark Bower
Mar 18, 2000·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·P Hermans
Jan 6, 2001·Sexually Transmitted Infections·T PowlesM Bower
Feb 11, 1998·Journal of Surgical Oncology·M von StritzkyJ G Pegels
May 20, 2003·Seminars in Dialysis·T K Sreepada Rao
Sep 17, 2004·Leukemia & Lymphoma·Melanie A ComitoKenneth G Lucas
Jan 29, 2000·Journal of Surgical Oncology·R J PlaceC L Simmang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.